[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thoracic-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thoracic-cancers":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":4,"leadSponsor":46,"locationsCount":49},"100075905","evaluation-of-cell-changes-in-blood-and-tissue-in-cancers-of-the-lung-esophagus-and-lung-lining-100075905",false,"NCT00242723","Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining","Prospective Evaluation of Genetic and Epigenetic Alterations in Patients With Thoracic Malignancies","* INCLUSION CRITERIA:\n\nPatients with potentially malignant or suspicious lesions, or with biopsy proven lung cancers or esophageal cancers, malignant pleural mesotheliomas, mediastinal or chest wall neoplasms, thymoma\u002Fthymic carcinomas, or thoracic metastases from cancers of non-thoracic origin.\n\nPatients must have an ECOG performance score of 0-2.\n\nPatients must be 2 years of age or older. Note: Patients \\>= 2 and \\\u003C 18 years of age may participate in research sample collection if the tissue acquisition is performed during a clinically indicated surgical procedure, and the sampling of tissue, blood and urine does not add risk to the clinically indicated procedures.\n\nPatients must be aware of the nature of his\u002Fher illness. The patient must be willing to undergo standard intervention that may include endoscopic biopsies of tumor and adjacent normal tissues, and to provide blood and urine samples to support ongoing laboratory research endeavors pertaining to the epigenetics of thoracic malignancies.\n\nAbility of subject, their parents\u002Fguardians or legally authorized representative (LAR) to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nNone.","ALL","2 Years","120 Years",{"count":20,"type":21},1559,"ESTIMATED","OBSERVATIONAL","Background:\n\n* Chromatin is is the structural building block of a chromosome. It is found inside the nucleus of the cell and consists of a complex of DNA and protein.\n* Cancers of the lung, pleura (lung lining) and esophagus show profound changes in chromatin structure that may affect the course of disease in patients.\n* A better understanding of these diseases and the genetic changes associated with them may be helpful in developing new treatments for them.\n\nObjectives:\n\n* To evaluate people with cancer of the lung, pleura or esophagus for participation in NCI clinical trials.\n* To obtain biopsies (small pieces of tissue) from tumor, normal tissue and blood samples to learn more about the cellular changes in blood and tissue in tumors of the lung, esophagus and pleura and surrounding structures in the chest.\n\nEligibility: Patients 2 years of age and older with cancer of the lung, esophagus, pleura, mediastinum or chest wall, or cancers of other origin that have invaded the lung. Note: Patients \\>= 2 years of age and under 18 years of age may only participate in research sample collection.\n\nDesign:\n\n* Up to 1310 patients may be included in this study.\n* Patients undergo standard tests for evaluating the stage of their disease and for determining eligibility for an NCI investigational treatment study.\n* All patients undergo bronchoscopy and bronchoalveolar lavage (\"washing\" with salt water) to assess their tumor and collect a sample of normal tissue. Patients whose tumor is located on the outside portion of the lung may also undergo thoracoscopy to obtain a tumor sample. For bronchoscopy and bronchoalveolar lavage a tube with a light is passed through the nose or mouth into the lungs to examine the airways. Salt water is injected through the tube and then withdrawn to obtain cells for laboratory studies. For the thoracoscopy a small tube with a light is put through a small hole in the chest to obtain the tumor sample. Both procedures are usually done under general anesthesia. The tissue is examined to identify cell characteristics of people who respond to certain therapies and to identify markers on the surface of the tissue that may be useful in future research and treatment.\n* Blood and urine samples are collected from patients.\n* Patients who are eligible for a treatment study at NCI are offered participation in the study.\n* Patients for whom standard surgery, radiation or chemotherapy is more appropriate may receive treatment at NCI or with their own physician.\n* Patients who receive treatment at NCI return for follow-up examinations 4 weeks after discharge and then every 2 to 4 months depending on the nature of their cancer.",[25,26,27,28,29],"Malignant Pleural Mesotheliomas NOS","Esophageal Cancers NOS","Lung Cancer NOS","Thoracic Cancers","Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura",[31,32,33,34,35,36,37,38],"Biopsy","Staging Studies","Screening","potentially malignant or suspicious lesions","Cancer Primary Evaluation","Lung Cancer","Esophageal Cancer","Malignant Pleural Mesothelioma","RECRUITING","2026-06-27",{"date":42,"type":43},"2026-06-30","ACTUAL",{"date":45,"type":43},"2005-11-09",{"name":47,"class":48},"National Cancer Institute (NCI)","NIH",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100568438","feasibility-study-of-cbct-for-igrt-in-cancer-patients-100568438","NCT06681233","Feasibility Study of CBCT for IGRT in Cancer Patients","A Feasibility Study of a Novel Cone-Beam CT Approach for Image Guided Radiotherapy in Cancer Patients","Inclusion Criteria:\n\n1. Patient age ≥ 18\n2. Patient is receiving radiation therapy for head and neck, thorax, liver, breast, genitourinary, or gastrointestinal malignancies\n3. A CBCT acquisition for localization is standard of care for the radiation therapy treatment plan being delivered\n\nExclusion Criteria:\n\n1. Patient has ECOG Performance Status ≥3.\n2. Patient is wheelchair bound.\n3. Patient has a life expectancy \\\u003C3 months.\n4. Patient is unwilling or unable to provide informed consent to participate in the study.\n5. Patient is pregnant or has plans for pregnancy during the period of treatment.\n6. Patient is part of a vulnerable population (per ISO 14155:2020, \"individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response\"). This includes prisoners.","18 Years",{"count":59,"type":21},50,"INTERVENTIONAL",[62],"NA","Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy but CBCT images have poor contrast and are susceptible to imaging artefacts that limit their usability for other tasks in the radiation therapy workflow.\n\nVarian Medical Systems, the sponsor of this study, has developed new CBCT imaging technology called HyperSight that so far has demonstrated increased image quality compared with conventional CBCT images. This new HyperSight CBCT imager has previously been built into Varian Halcyon and Ethos treatment machines, where the imager is enclosed in a ring that rotates around the patient. Now, HyperSight has been built into a Varian treatment machine, called TrueBeam, where the imager is mounted on a C-shaped arm that rotates around you to acquire an image.\n\nThis study is being done to evaluate the image quality of HyperSight CBCT compared to conventional CBCT images, and to determine whether HyperSight CBCT can improve the process of delivering radiation treatments.\n\nThe goal of this study is to collect images from this new HyperSight-TrueBeam CBCT imager from a variety of patients and locations in the body. The images will be analyzed to determine whether their quality is high enough to use for tasks other than positioning patients for treatment. For example, the study will determine whether the HyperSight images could be used to calculate a radiation plan.",[65,66,28,67,68,69],"Head and Neck Cancers","Breast Cancer","Liver Cancer","Genito Urinary Cancer","Gastrointestinal Cancers","2026-03-12",{"date":72,"type":43},"2026-03-13",{"date":74,"type":43},"2025-02-19",{"date":76,"type":21},"2026-09",{"name":78,"class":79},"Varian, a Siemens Healthineers Company","INDUSTRY",4]